ATS 2026: Metabolite ratios may predict omalizumab response in severe asthma

Linking metabolomics to patient outcomes could help guide a precision medicine approach to severe asthma. Linking metabolomics to patient outcomes could help guide a precision medicine approach to severe asthma. ATS 2026 findings suggest a link between certain metabolite ratios and patient responses to Xolair in severe asthma. Credit: Pixel-Shot/Shutterstock.com On 18 May, at the American Thoracic Society (ATS) 2026 annual meeting, a cohort analysis of the Study of Mechanisms of Action of Omalizumab in Severe Asthma (SoMOSA) (ISRCTN15124178) was presented. SoMOSA is an open-label, real-world study undertaken at 18 hospitals within the UK National Health Service (NHS) system, in…

Source: Clinical Trials Arena